{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:08:54Z","timestamp":1794024534964,"version":"4.8.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":708,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the effects of Cimlanod, a nitroxyl donor with vasodilator properties, on water and salt excretion after an administration of an intravenos bolus of furosemide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In this randomized, double-blind, mechanistic, crossover trial, 21 patients with left ventricular ejection fraction &amp;lt;45%, increased plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and receiving loop diuretics were given, on separate study days, either an 8\u2009h intravenous (IV) infusion of cimlanod (12\u2009\u03bcg\/kg\/min) or placebo. Furosemide was given as a 40\u2009mg IV bolus four hours after the start of infusion. The primary endpoint was urine volume in the 4\u2009h after the bolus of furosemide during infusion of cimlanod compared with placebo. Median NT-proBNP at baseline was 1487 (interquartile range: 847\u20132665) ng\/L. Infusion of cimlanod increased cardiac output and reduced blood pressure without affecting cardiac power index consistent with its vasodilator effects. Urine volume in the 4\u2009h post-furosemide was lower with cimlanod (1032\u2009\u00b1\u2009393\u2009ml) versus placebo (1481\u2009\u00b1\u2009560\u2009ml) (p\u2009=\u20090.002), as were total sodium excretion (p\u2009=\u20090.004), fractional sodium excretion (p\u2009=\u20090.016), systolic blood pressure (p\u2009&amp;lt;\u20090.001), estimated glomerular filtration rate (p\u2009=\u20090.012), and haemoglobin (p\u2009=\u20090.010), an index of plasma volume expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For patients with heart failure and congestion, vasodilatation with agents such as cimlanod reduces the response to diuretic agents, which may offset any benefit from acute reductions in cardiac preload and afterload.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3077","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T07:31:22Z","timestamp":1700638282000},"page":"142-151","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of Vasodilators on Diuretic Response in Patients with Congestive Heart Failure: A Mechanistic Trial of Cimlanod (BMS-986231)"],"prefix":"10.1093","volume":"26","author":[{"given":"Pierpaolo","family":"Pellicori","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Borentain","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Taubel","sequence":"additional","affiliation":[{"name":"Richmond Pharmacology Ltd, St. George's University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser J.","family":"Graham","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Khan","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bruzzese","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u2018Federico II\u2019 , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kessler","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University of Groningen, Department of Cardiology, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Inova Heart and Vascular Institute , Falls Church, VA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine and the Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"2026010913073720600_ejhf3077-bib-0001","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0140-6736(83)92025-1","article-title":"Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart-failure following myocardial infarction","volume":"1","author":"Nelson","year":"1983","journal-title":"Lancet"},{"key":"2026010913073720600_ejhf3077-bib-0002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)08417-1","article-title":"Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema","volume":"351","author":"Cotter","year":"1998","journal-title":"Lancet"},{"key":"2026010913073720600_ejhf3077-bib-0003","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026010913073720600_ejhf3077-bib-0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0005","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 Cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"2026010913073720600_ejhf3077-bib-0006","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2019.18598","article-title":"Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: The GALACTIC randomized clinical trial","volume":"322","author":"Kozhuharov","year":"2019","journal-title":"JAMA"},{"key":"2026010913073720600_ejhf3077-bib-0007","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamacardio.2019.5108","article-title":"Global differences in characteristics, precipitants, and initial management of patients presenting with acute heart failure","volume":"5","author":"Filippatos","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026010913073720600_ejhf3077-bib-0008","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/eurheartj\/ehab082","article-title":"The struggle towards a universal definition of heart failure \u2013 How to proceed?","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913073720600_ejhf3077-bib-0009","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","article-title":"Diuretic response in acute heart failure: Clinical characteristics and prognostic significance","volume":"35","author":"Valente","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010913073720600_ejhf3077-bib-0010","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","article-title":"Cardiac dysfunction, congestion and loop diuretics: Their relationship to prognosis in heart failure","volume":"30","author":"Pellicori","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026010913073720600_ejhf3077-bib-0011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-012-9306-2","article-title":"Renal dysfunction in acute and chronic heart failure: Prevalence, incidence and prognosis","volume":"17","author":"Cleland","year":"2012","journal-title":"Heart Fail Rev"},{"key":"2026010913073720600_ejhf3077-bib-0012","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ejhf.2032","article-title":"Ultrasound imaging of congestion in heart failure: Examinations beyond the heart","volume":"23","author":"Pellicori","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0013","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0735-1097(10)80342-0","article-title":"Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine","volume":"16","author":"Dupuis","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"2026010913073720600_ejhf3077-bib-0014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/01.CIR.90.1.220","article-title":"Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition","volume":"90","author":"Good","year":"1994","journal-title":"Circulation"},{"key":"2026010913073720600_ejhf3077-bib-0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: The PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0016","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ejhf.1504","article-title":"Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure","volume":"21","author":"Felker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0017","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jchf.2020.10.012","article-title":"Effects of a novel nitroxyl donor in acute heart failure: The STAND-UP AHF study","volume":"9","author":"Felker","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0018","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jcph.1364","article-title":"A phase 1 randomized study of single intravenous infusions of the novel nitroxyl donor BMS-986231 in healthy volunteers","volume":"59","author":"Cowart","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2026010913073720600_ejhf3077-bib-0019","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/ars.2010.3269","article-title":"Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: Comparison with GTN and DEA\/NO","volume":"14","author":"Irvine","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"2026010913073720600_ejhf3077-bib-0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ejhf.748","article-title":"The effects of short-term omission of daily medication on the pathophysiology of heart failure","volume":"19","author":"Dovancescu","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0021","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/ejhf.1383","article-title":"Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure","volume":"21","author":"Pellicori","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0022","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ejhf.193","article-title":"Calculated plasma volume status and prognosis in chronic heart failure","volume":"17","author":"Ling","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0023","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1378\/chest.125.4.1431","article-title":"Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance","volume":"125","author":"Cotter","year":"2004","journal-title":"Chest"},{"key":"2026010913073720600_ejhf3077-bib-0024","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/aca.ACA_1_19","article-title":"Comparison of continuous cardiac output monitoring derived from regional impedance cardiography with continuous thermodilution technique in cardiac surgical patients","volume":"23","author":"Bhavya","year":"2020","journal-title":"Ann Card Anaesth"},{"key":"2026010913073720600_ejhf3077-bib-0025","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2022"},{"key":"2026010913073720600_ejhf3077-bib-0026","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ejhf.2138","article-title":"Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: A randomized trial","volume":"23","author":"Lang","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0027","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/ejhf.153","article-title":"Breathlessness at rest is not the dominant presentation of patients admitted with heart failure","volume":"16","author":"Shoaib","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0028","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0002-8703(82)90229-0","article-title":"Minoxidil therapy in chronic congestive heart failure: Acute plus long-term hemodynamic and clinical study","volume":"104","author":"McKay","year":"1982","journal-title":"Am Heart J"},{"key":"2026010913073720600_ejhf3077-bib-0029","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/oxfordjournals.eurheartj.a060362","article-title":"The short-term effect of intravenous nitroglycerin on haematocrit; an additional benefit in patients with myocardial ischaemia?","volume":"15","author":"Arend","year":"1994","journal-title":"Eur Heart J"},{"key":"2026010913073720600_ejhf3077-bib-0030","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.CIR.84.6.2336","article-title":"Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin","volume":"84","author":"Parker","year":"1991","journal-title":"Circulation"},{"key":"2026010913073720600_ejhf3077-bib-0031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.CIR.83.1.191","article-title":"Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure","volume":"83","author":"M\u00fcnzel","year":"1991","journal-title":"Circulation"},{"key":"2026010913073720600_ejhf3077-bib-0032","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cardfail.2007.12.002","article-title":"The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction","volume":"14","author":"Owan","year":"2008","journal-title":"J Card Fail"},{"key":"2026010913073720600_ejhf3077-bib-0033","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/clc.20787","article-title":"Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction","volume":"33","author":"Sica","year":"2010","journal-title":"Clin Cardiol"},{"key":"2026010913073720600_ejhf3077-bib-0034","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"2026010913073720600_ejhf3077-bib-0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ahj.2015.05.003","article-title":"Diuretic response in acute heart failure \u2013 An analysis from ASCEND-HF","volume":"170","author":"ter Maaten","year":"2015","journal-title":"Am Heart J"},{"key":"2026010913073720600_ejhf3077-bib-0036","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002593","article-title":"Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction: Results from the ROSE AHF trial (Renal Optimization Strategies Evaluation in Acute Heart Failure)","volume":"9","author":"Wan","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0037","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913073720600_ejhf3077-bib-0038","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"2026010913073720600_ejhf3077-bib-0039","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.170","article-title":"Diuretic response in patients with acute decompensated heart failure: Characteristics and clinical outcome \u2013 An analysis from RELAX-AHF","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913073720600_ejhf3077-bib-0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2017.05.012","article-title":"Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial","volume":"190","author":"Gimpelewicz","year":"2017","journal-title":"Am Heart J"},{"key":"2026010913073720600_ejhf3077-bib-0041","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/CIRCRESAHA.121.318186","article-title":"Pathophysiology and therapeutic approaches to acute decompensated heart failure","volume":"128","author":"Njoroge","year":"2021","journal-title":"Circ Res"},{"key":"2026010913073720600_ejhf3077-bib-0042","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrcardio.2012.191","article-title":"Causes and treatment of oedema in patients with heart failure","volume":"10","author":"Clark","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2026010913073720600_ejhf3077-bib-0043","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FJC.0000000000000262","article-title":"Development of a human model for the study of effects of hypoxia, exercise, and sildenafil on cardiac and vascular function in chronic heart failure","volume":"66","author":"Damy","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026010913073720600_ejhf3077-bib-0044","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.lfs.2012.07.034","article-title":"Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?","volume":"91","author":"Kohan","year":"2012","journal-title":"Life Sci"},{"key":"2026010913073720600_ejhf3077-bib-0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/hrt.66.4.264","article-title":"Vascular tone in heart failure: The neuroendocrine-therapeutic interface","volume":"66","author":"Cleland","year":"1991","journal-title":"Br Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/1\/142\/65513892\/eurjhf_26_1_142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/1\/142\/65513892\/eurjhf_26_1_142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:29Z","timestamp":1767982169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/1\/142\/8328857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3077","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"2023-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}